Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial

Mass Spectrometry Imaging Reveals Heterogeneous Efavirenz Distribution within Putative HIV Reservoirs

(2015) Corbin G. Thompson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rifaximin has a Marginal Impact on Microbial Translocation, T-cell Activation and Inflammation in HIV-Positive Immune Non-responders to Antiretroviral Therapy – ACTG A5286

(2014) Allan R. Tenorio et al.   JOURNAL OF INFECTIOUS DISEASES

Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non–AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment

(2014) Allan R. Tenorio et al.   JOURNAL OF INFECTIOUS DISEASES

Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection

(2014) Peter W. Hunt et al.   JOURNAL OF INFECTIOUS DISEASES

Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals

(2014) J F Vázquez-Castellanos et al.   Mucosal Immunology

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

(2014) Courtney V. Fletcher et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD8 T cell persistence in treated HIV infection

(2014) Joseph C. Mudd et al.   Current Opinion in HIV and AIDS

Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation

(2014) Alexandra Schuetz et al.   PLoS Pathogens

HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality

(2014) Sergio Serrano-Villar et al.   PLoS Pathogens

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial

(2014) Alain Lafeuillade et al.   AIDS Research and Therapy

Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment

(2013) Carolina Gutiérrez et al.   AIDS

Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy

(2013) David M. Asmuth et al.   AIDS

Differential penetration of raltegravir throughout gastrointestinal tissue

(2013) Kristine B. Patterson et al.   AIDS

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection

(2013) Maria C. Puertas et al.   AIDS

The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial

(2013) P. W. Hunt et al.   BLOOD

Alterations in the Gut Microbiota Associated with HIV-1 Infection

(2013) Catherine A. Lozupone et al.   Cell Host & Microbe

Systemic Effects of Inflammation on Health during Chronic HIV Infection

(2013) Steven G. Deeks et al.   IMMUNITY

Immune activation and HIV persistence: implications for curative approaches to HIV infection

(2013) Nichole R. Klatt et al.   IMMUNOLOGICAL REVIEWS

Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy

(2013) Eugènia Negredo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Unique Features of Naive CD8+ T Cell Activation by IL-2

(2013) J.-H. Cho et al.   JOURNAL OF IMMUNOLOGY

Increase in 2–Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial

(2013) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

Impaired CD4+ T-Cell Restoration in the Small Versus Large Intestine of HIV-1–Positive South Africans Receiving Combination Antiretroviral Therapy

(2013) Edana Cassol et al.   JOURNAL OF INFECTIOUS DISEASES

Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size

(2013) Vivek Jain et al.   JOURNAL OF INFECTIOUS DISEASES

Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism

(2013) Ivan Vujkovic-Cvijin et al.   Science Translational Medicine

Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens

(2012) David M. Asmuth et al.   AIDS

A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256

(2012) T. J. Wilkin et al.   JOURNAL OF INFECTIOUS DISEASES

Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection

(2012) Jintanat Ananworanich et al.   PLoS One

Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy

(2011) Duncan Chege et al.   AIDS

No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy

(2011) Rajesh T. Gandhi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response

(2011) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative Men

(2011) Kevin C. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

(2011) Netanya G. Sandler et al.   JOURNAL OF INFECTIOUS DISEASES

Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

(2011) Carolina Gutiérrez et al.   PLoS One

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

(2010) Steven A Yukl et al.   AIDS

HIV Infection, Inflammation, Immunosenescence, and Aging

(2010) Steven G. Deeks   Annual Review of Medicine

Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1

(2010) D. Croteau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2

(2010) David M Asmuth et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV

(2010) B. M. Best et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Disruption of Intestinal CD4+ T Cell Homeostasis Is a Key Marker of Systemic CD4+ T Cell Activation in HIV-Infected Individuals

(2010) S. N. Gordon et al.   JOURNAL OF IMMUNOLOGY

Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy

(2010) Steven A. Yukl et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients

(2010) Nicholas Funderburg et al.   PLoS One

Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections

(2010) Jacob D. Estes et al.   PLoS Pathogens

Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States

(2009) Emilie Lanoy et al.   AIDS

Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384

(2009) Gregory K. Robbins et al.   CLINICAL INFECTIOUS DISEASES

Simian Immunodeficiency Virus–Induced Intestinal Cell Apoptosis Is the Underlying Mechanism of the Regenerative Enteropathy of Early Infection

(2008) Qingsheng Li et al.   JOURNAL OF INFECTIOUS DISEASES

Persistence of HIV in Gut‐Associated Lymphoid Tissue despite Long‐Term Antiretroviral Therapy

(2008) Tae‐Wook Chun et al.   JOURNAL OF INFECTIOUS DISEASES

CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIVmac251 infection

(2008) M Vaccari et al.   Mucosal Immunology

Incremental predictive value of vascular assessments combined with the Framingham Risk Score for prediction of coronary events in subjects of low-intermediate risk

(2008) K-K Lau et al.   POSTGRADUATE MEDICAL JOURNAL

Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT)

(2008) D. K. Walker et al.   XENOBIOTICA